

IMPORTANT NOTICE

THIS CELL SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH
THE CONSTITUTION AND PROPECTUS OF
TURQUOISE CAPITAL INVESTMENT FUND PCC UPDATED ON 03
SEPTEMBER 2025

CELL SUPPLEMENT

FOR

**TURQUOISE CAPITAL INVESTMENT FUND PCC –
AVENTURINE ALTERNATIVES CELL**

Updated on 3rd September 2025



1. ABOUT AVENTURINE ALTERNATIVES CELL

This Cell Supplement contains only key information about AVENTURINE ALTERNATIVES a Cell of TURQUOISE CAPITAL INVESTMENT FUND PCC (“AVENTURINE ALTERNATIVES CELL”).

TURQUOISE CAPITAL INVESTMENT FUND PCC (the "**Company**") has been established as a private company limited by shares on 22 June 2023, holding a Global Business Licence and operating as a Collective Investment Scheme, authorised as a Global Scheme under Regulation 16 of The Securities (Collective Investment Scheme and Closed-end Funds) Regulations 2008 and structured as a protected cell company ("**PCC**") to engage in investment activities, as described under the Protected Cell Companies Act 1999, as amended.

In granting this authorisation, it must be clearly understood that the FSC does not vouch for the financial soundness of the Company or for the correctness of any statements made herein or any opinions expressed with regards to them.

The Directors of the Company accept responsibility for the information contained herein. To the best of the knowledge and belief of the Directors, who have taken all reasonable care to ensure that such is the case, the information provided in this document is in accordance with the facts and contains a fair summary of the key information set out in the full Prospectus. The information contained in this Cell Supplement should be read in conjunction with the full text of the Prospectus. It is the responsibility of each person relying on this Cell Supplement to ensure that the said document is the latest one issued.

2. ANTI-MONEY LAUNDERING PROVISIONS

The Financial Intelligence and Anti-Money Laundering Act 2002 provides for the offences of money laundering, the reporting of suspicious transactions and the measures to combat money laundering. A money laundering offence is committed when a person engages in a transaction that involves property which is or represents the proceeds of any crime or receives, is in possession of, conceals, disguises, transfers, converts, disposes of, removes from or brings into Mauritius any property which is or represents the proceeds of any crime. The Act also lays down the obligation on “every bank, financial institution, cash dealer or member of a relevant profession or occupation” to report forthwith to the Financial Intelligence Unit (FIU) any “suspicious transaction”. To satisfy the requirements under this Act, the Company may require additional evidence of identification from a prospective investor prior to issuing units. Besides existing legislation, the Cells will also adhere to the requirements of the relevant codes, guidelines and handbooks on Prevention of Money Laundering issued by the FSC.

3. SHAREHOLDERS

The Company will issue Participating Shares to prospective subscribers. The number of Participating Shares to be issued shall depend on the amount of subscription monies received for such Participating Shares. On purchase and redemption of Participating Shares, the Fund Administrator will make an entry in the register of unitholders, which is the definitive evidence

TURQUOISE CAPITAL INVESTMENT FUND PCC – AVENTURINE ALTERNATIVES CELL

Cell Supplement

of holding in the Cell.

Participating Shares may be subscribed or redeemed on the first Business Day of each month and/or such other day or days as the Directors may, in their discretion determine. Notice for subscription or redemption shall be as per the Company's constitution as may be amended from time to time by the directors.

4. FUNCTIONARIES

Function	Company	Address
CIS Manager	Providentia Fund Managers Ltd	Level 4, Ebene House 33, Hotel Avenue Cybercity, Ebene, 72201 Republic of Mauritius
Fund Administrator	JurisTax Ltd	Level 3, Ebene House 33, Hotel Avenue Cybercity, Ebene, 72201 Republic of Mauritius
Principal Distributor	Providentia Asset Managers Ltd	Level 4, Ebene House 33, Hotel Avenue Cybercity, Ebene, 72201 Republic of Mauritius
Auditor	Ecovis (Mauritius)	Suite 207-2 nd Floor, NG Tower, Cybercity, Ebene, Mauritius
Prime Broker & Custodian	The Mauritius Commercial Bank Limited	MCB Head Office, 9-15 Sir William Newton Street, Port Louis, Mauritius
Banker	Absa Bank (Mauritius) Limited	Absa House, 68-68A, Wall Street, Cybercity, Ebene 72201, Mauritius

5. DOCUMENTS AVAILABLE FOR INSPECTION

The following documents, which form part of the constitutive documents of the Company, are available, free of charge, for inspection at the office of the CIS Manager having office registered address at C/o JurisTax Ltd, Level 3, Ebene House, Hotel Avenue, 33 Cybercity, Ebene 72201, Mauritius, during office hours:

1. The Constitution of the Company
2. The full updated Prospectus dated 3rd September 2025
3. The annual and interim management report

6. INVESTMENT OBJECTIVE OF THE CELL

The Cell seeks to generate returns that have low correlation with the returns of the stock and bond markets and seeks capital appreciation.

The objective is to be achieved by investing principally in the following securities:

- 1) Debts such as sovereign debts, corporate debts, credit notes, capital protected notes, structured notes, debentures, bonds, and any investment related to debts
- 2) Exchange Traded Funds securities
- 3) Future and forward securities and bonds
- 4) Money market
- 5) Hybrid investment instruments such as convertible debenture, convertible bonds and any other hybrid investment instruments.

Alternative investments offer greater portfolio diversification and lower overall risk with the potential for higher returns. The Cell will invest primarily in listed securities offering access to any of the following:

- 1) Private Equity
- 2) Megatrend Equities
- 3) Real Estate
- 4) Commodities
- 5) Structured Products
- 6) Digital Assets

It is intended to invest a majority of the assets in USD denominated investment grade securities.

7. DIVIDENDS

No dividend shall be payable by the Cell.

8. REGULATORY COMPLIANCE AND INVESTMENT RESTRICTIONS

Each Cell shall conduct its investment activities as set out in the Company's Prospectus, this Cell Supplement and in compliance with Regulations 65, 66, and 68 of the Securities (Collective Investment Schemes and Closed-end Funds) Regulations 2008 ("CIS Regulations"), as amended. Accordingly, the Cell shall adhere to the prescribed investment restrictions and practices relating, inter alia, to concentration limits, borrowing, underwriting, lending, and transactions with related parties. Notwithstanding its distinct investment objectives and strategies, the Cell shall ensure that its investment operations remain consistent with the regulatory framework, save where any exemption or variation has been duly approved by the Financial Services Commission in accordance with Regulation 67. The Cell's investment policy and risk parameters shall, at all times, reflect compliance with the applicable regulatory limits and disclosure requirements.

The Cell has obtained an exemption in relation to Regulation 65 (a) of the CIS Regulations from the Financial Services Commission as provided under Regulation 67, permitting it to increase its investment exposure to a single issuer from 5% to 15% of its net asset value.

9. GENERAL RISK FACTORS

Any investment carries a level of risk that generally reflects its potential for reward. Neither the CIS Manager, Fund Administrator, the Principal Distributor, nor any other functionary guarantees the performance of the Funds, the attainment of the stated objectives, or the repayment of capital.

- Investors are not certain to make a profit and in certain circumstances they may even lose money. Any income is not fixed. The value of investments and any income derived from them can go up as well as down.
- Losses may be made due to adverse movements in equity, bond, currency and other market prices and to changes in the volatility of any of these. The key factors driving changes in these market prices are economic growth and inflation, both of which themselves depend to a greater or lesser extent on official economic and interest rate policy.
- Investors are advised to contact an independent financial adviser if they are in any doubt about the suitability of an investment in the Cell, or if they are not confident that they fully understand the risks involved.
- The past performance of the Funds should not be taken as a guide to their future performance. Funds that have performed well in the past may perform poorly in the future and vice versa.
- Greater exposure to individual securities reduces diversification and increases issuer, sector, and volatility risks, making the Cell's performance more sensitive to adverse developments and market events. Concentration risk is mitigated through internal target limits with pre-trade controls, daily monitoring, monthly Investment Committee reviews (hard cap 15%), and independent oversight via quarterly Board reporting.

Other risk factors applicable to the relevant Company are fully described in the Prospectus.

10. MINIMUM SUBSCRIPTION

The Minimum Initial Subscription per subscriber is USD10,000 (or equivalent in EURO or GBP or MUR) and the minimum additional investment for an existing Shareholder shall either be a Lump Sum Payment and/ or opt for a regular savings plan.

- i) The minimum additional Lump Sum investment per Shareholder shall be USD5,000 (or equivalent in EURO or GBP or MUR).
- ii) Regular Savings Plan Investors shall also be given the option of subscribing to a Systematic Investment Plan. Payment shall be effected in the following ways:
 - a) **Monthly:** The Monthly savings plan shall carry a minimum monthly subscription of USD 250 or MUR10,000 (or equivalent EUR or GBP)
 - b) **Quarterly:** The quarterly savings plan shall carry a minimum quarterly subscription of USD 1,000 or MUR50,000 (or equivalent EUR or GBP)

The Cell will be denominated in USD although it can accept subscriptions in MUR, GBP, USD and EUR.

11. FEES & EXPENSES

All initial costs and expenses associated with the organisation, including the costs incurred in connection with the preparation of the Cell Supplement, registration fees and expenses incurred in the establishment of the Cell shall be borne by the promoter.

Other main recurring fees, which is payable by the Cell, are as follows:

Entry Fees	Exit fee	Switch Fee	Manager Fee (per annum)	Other Fees per annum)	Expense Ratio (per annum)
1%	Nil	Nil	1.25%	0.25%	1.50%